Evidence map›Paper›PMID 36591281›Full record

ArticleFrontiers in immunology2022

T cell repertoire profiling in allografts and native tissues in recipients with COVID-19 after solid organ transplantation: Insight into T cell-mediated allograft protection from viral infection.

Jianing Fu, Dylan Rust, Zhou Fang, Wenyu Jiao, Stephen Lagana, Ibrahim Batal, Bryan Chen, Sarah Merl, Rebecca Jones, Megan Sykes and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jianing FuColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, NY, United States.
Dylan RustColumbia University Vagelos College of Physicians and Surgeons, New York, NY, United States.
Zhou FangColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, NY, United States.
Wenyu JiaoColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, NY, United States.
Stephen LaganaDepartment of Pathology, Columbia University, New York, NY, United States.
Ibrahim BatalDepartment of Pathology, Columbia University, New York, NY, United States.
Bryan ChenColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, NY, United States.
Sarah MerlColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, NY, United States.
Rebecca JonesColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, NY, United States.
Megan SykesColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, NY, United States.
Joshua WeinerColumbia Center for Translational Immunology, Department of Medicine, Columbia University, New York, NY, United States.
Columbia University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The effects of the SARS-CoV-2 virus on the body, and why the effects are more severe in certain patients, remain incompletely understood. One population of special interest is transplant recipients because of their immunosuppressed state. Understanding the pathophysiology of graft dysfunction in transplant patients with the COVID-19 viral syndrome is important for prognosticating the risk to the graft as well as understanding how best to prevent and, if necessary, treat graft injury in these patients. Methods: We analyzed multiple types of solid organ transplant recipients (liver, kidney, heart or lung) at our institution who died from SARS-CoV-2 and underwent autopsy (n = 6) or whose grafts were biopsied during active SARS-CoV-2 infection (n = 8). Their serum inflammatory markers were examined together with the histological appearance, viral load, and TCR repertoire of their graft tissue and, for autopsy patients, several native tissues. Results: Histology and clinical lab results revealed a systemic inflammatory pattern that included elevated inflammatory markers and diffuse tissue damage regardless of graft rejection. Virus was detected throughout all tissues, although most abundant in lungs. The TCR repertoire was broadly similar throughout the tissues of each individual, with greater sharing of dominant clones associated with more rapid disease course. There was no difference in viral load or clonal distribution of overall, COVID-associated, or putative SARS-CoV-2-specific TCRs between allograft and native tissue. We further demonstrated that SARSCoV-2-specific TCR sequences in transplant patients lack a donor HLArestricted pattern, regardless of distribution in allograft or native tissues,suggesting that recognition of viral antigens on infiltrating recipient cells can effectively trigger host T cell anti-viral responses in both the host and graft. Discussion: Our findings suggest a systemic immune response to the SARS-CoV-2 virus in solid organ transplant patients that is not associated with rejection and consistent with a largely destructive effect of recipient HLA-restricted T cell clones that affects donor and native organs similarly.

Indexed as

COVID-19Organ TransplantationAllograftsHumansReceptors, Antigen, T-CellSARS-CoV-2T-LymphocytesReceptors, Antigen, T-CellCOVID–19immune responseimmunosuppressedSARS–CoV–2T cellT cell repertoire analysistransplant recipientsviral response

Identifiers

PMID36591281
PMCPMC9795050
OpenAlexW4311380790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.